Erythropoietic porphyria is a genetic disease resulting in the deposition of porphyrins throughout the body.
2.
Defects in ferrochelatase create a buildup of protoporphyrin IX, causing erythropoietic protoporphyria ( EPP ).
3.
A deficiency is associated with Gunther's disease, also known as congenital erythropoietic porphyria ( CEP ).
4.
The pain, burning, swelling, and itching that occur in erythropoietic porphyrias generally require avoidance of bright sunlight.
5.
The rarest is congenital erythropoietic porphyria ( C . E . P ), otherwise known as Gunther's disease.
6.
Erythropoietin is the primary erythropoietic factor that cooperates with various other growth factors ( e . g ., multipotent progenitors.
7.
It should also be noted that quite a bit of research emphesis is on non erythropoietic but, neuroprotective Peptides of Erythropoietin.
8.
This suggests a possible extra-ribosomal function for this gene in erythropoietic differentiation and proliferation, in addition to its ribosomal function.
9.
Peptide of Epo with amino acids 92-111 is neuroprotective while its erythropoietic potency is 10 fold less than the wild type.
10.
The U . S . Food and Drug Administration have recognized afamelanotide as an orphan drug for the treatment of EPP and congenital erythropoietic porphyria.
